

API & FDF

Product List


***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patents related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

OUR GLOBAL OPERATIONS

756 Million Patients Reached*
Our vision to reach 1.5 billion people across the globe



OUR VERTICALS



ESG GOALS & SUSTAINABILITY



PRODUCT NAME - COMMERCIAL*		THERAPY AREA	China DMF	US DMF	EU DMF	CEP	DOSAGE FORM	FORMULATION AVAILABILITY#
A	Abiraterone Acetate	Oncology	A	✓	✓	•	Tablets	Yes
	Amlodipine Besylate	Cardiology	A	✓	•	✓	Tablets	Yes
	Apalutamide (Amorphous and Form B)	Oncology	•	✓	•	•	Tablets	Yes
	Apixaban	Cardiology	A	✓	✓	•	Tablets	Yes
	Apremilast (Form B)	Central Nervous System	I	✓	•	•	Tablets	Yes
	Atomoxetine Hydrochloride	Central Nervous System	A	✓	•	•	Capsules/Tablets	Yes
	Atorvastatin Calcium (Amorphous & Form P)	Cardiology	•	✓	✓	•	Tablets	Yes
	Atorvastatin Calcium (Form 1)	Cardiology	A	✓	✓	✓	Tablets	Yes
	Azacitidine	Oncology	A	✓	✓	•	Tablets/Injection	Yes
B	Bempedoic Acid	Cardiology	•	✓	•	•	Tablets	Yes
	Bendamustine Hydrochloride	Oncology	•	✓	✓	•	Injection	No
	Benztropine Mesylate	Central Nervous System	•	✓	•	•	Tablets/Injection	Yes
	Bortezomib	Oncology	•	✓	✓	•	Injection	Yes
C	Cabazitaxel	Oncology	•	✓	✓	•	Injection	Yes
	Cabozantinib Hydrochloride	Oncology	•	✓	•	•	Tablets	No
	Cabozantinib S-Malate	Oncology	•	✓	•	•	Tablets	Yes
	Capecitabine	Oncology	A	✓	•	✓	Tablets	Yes
	Carfilzomib	Oncology	I	✓	✓	•	Injection	Yes
	Cetirizine Dihydrochloride	Respiratory	•	✓	✓	✓	Tablets	Yes
	Cinacalcet Hydrochloride	Others	A	✓	✓	•	Tablets	Yes
	Ciprofloxacin Hydrochloride	Anti-Infective	A	✓	•	✓	Tablets	Yes
	Clopidogrel Bisulfate (Form 1)	Cardiology	A	✓	•	✓	Tablets	Yes
	Clopidogrel Bisulfate (Form 2)	Cardiology	A	✓	✓	✓	Tablets	Yes

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Note: A - Active; I - Inactive

Yes/No relates to availability* of Formulation

PRODUCT NAME - COMMERCIAL*		THERAPY AREA	China DMF	US DMF	EU DMF	CEP	DOSAGE FORM	FORMULATION AVAILABILITY#
D	Dabigatran Etexilate Mesylate	Cardiology	A	✓	✓	✓	Capsules	Yes
	Dapagliflozin (Amorphous)	Anti-Diabetic	A	✓	✓	•	Tablets	No
	Dapagliflozin (Propanediol Monohydrate)	Anti-Diabetic	A	✓	✓	•	Tablets	Yes
	Dasatinib Monohydrate	Oncology	A	✓	•	•	Tablets	Yes
	Decitabine	Oncology	•	✓	•	•	Injection	Yes
	Deucravacitinib	Oncology	•	✓	•	•	Tablets	Yes
	Dimethyl Fumarate	Central Nervous System	A	✓	✓	•	Capsules	Yes
	Donepezil Hydrochloride Monohydrate (Form-1)	Central Nervous System	•	✓	✓	•	Tablets	Yes
	Doxazosin Mesylate	Cardiology	•	✓	•	✓	Tablets	No
	Dutasteride (Form 2)	Urology	I	✓	✓	•	Capsules	No
E	Edaravone	Central Nervous System	•	✓	✓	•	Injection	Yes
	Edoxoban Tosylate Monohydrate	Cardiology	•	✓	✓	•	Tablets	Yes
	Elagolix Sodium	Pain Management	•	✓	•	•	Capsules	Yes
	Empagliflozin	Anti-Diabetic	•	✓	✓	•	Tablets	Yes
	Enalapril Maleate	Cardiology	•	✓	•	✓	Tablets	Yes
	Enzalutamide	Oncology	A	✓	•	•		
	Enzalutamide (Crystalline & Premix)	Oncology	•	✓	✓	•	Capsules/Tablets	Yes
	Eribulin Mesylate	Oncology	•	✓	✓	•	Injection	Yes
	Eslicarbazepine Acetate	Central Nervous System	•	✓	✓	•	Tablets	Yes
	Esomeprazole Magnesium Trihydrate	Gastro-Intestinal	A	✓	✓	✓	Capsules	Yes
	Eszopiclone	Central Nervous System	•	✓	•	•	Tablets	Yes
	Ezetimibe	Cardiology	•	✓	✓	•	Tablets	No
F	Famotidine	Gastro-Intestinal	I	✓	•	✓	Tablets	Yes
	Ferric Carboxymaltose	Nephrology	•	✓	✓	•	Injection	Yes
	Fexofenadine Hydrochloride (Form 1)	Respiratory	•	✓	✓	✓	Tablets	Yes

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Note: A - Active; I - Inactive

Yes/No relates to availability* of Formulation

PRODUCT NAME - COMMERCIAL*		THERAPY AREA	China DMF	US DMF	EU DMF	CEP	DOSAGE FORM	FORMULATION AVAILABILITY#
	Fluoxetine	Central Nervous System	A	✓	✓	✓	Capsules/ Tablets Oral Solution	Yes
	Finasteride (Form 1)	Central Nervous System	I	✓	•	•	Tablets	Yes
	Finasteride (Form 3)	Central Nervous System	•	✓	•	✓	Tablets	Yes
	Fondaparinux Sodium	Cardiology	A	✓	✓	•	Injection	Yes
	Fosaprepitant	Oncology	•	✓	•	•	Injection /Tablets	Yes
G	Gatifloxacin Anhydrous	Anti-Infective	•	✓	•	•	Tablets/solution	No
	Gemcitabine Hydrochloride	Oncology	A	✓	•	✓	Injection	Yes
	Glimepiride	Anti-Diabetic	•	✓	•	✓	Tablets	Yes
	Granisetron	Oncology	•	✓	✓	•	Injection /Tablets	No
H	Hydroxychloroquine	Anti-Infective	•	✓	•	•	Tablets	Yes
K	Ketorolac Tromethamine	Pain Management	A	✓	•	✓	Injection /Tablets	Yes
L	Lacidipine	Cardiology	•	•	✓	•	Tablets	Yes
	Lenalidomide (Form A)	Oncology	A	✓	✓	•	Capsules	Yes
	Lenvatinib Mesylate (Form C and MIBK Solvate)	Oncology	•	✓	•	•	Capsules	Yes
	Levetiracetam	Central Nervous System	A	✓	•	✓	Injection /Tablets	Yes
	Levocetirizine Dihydrochloride	Respiratory	•	✓	✓	✓	Tablets	Yes
	Levofloxacin Hemihydrate	Anti-Infective	•	✓	✓	✓	Injection /Tablets	Yes
	Lifitegrast	Ophthalmology	•	✓	•	•	Eye drop	Yes
	Linagliptin (Mix of Form A and B)	Anti-Diabetic	•	✓	✓	•	Tablets	Yes
	Liraglutide	Anti-Diabetic	•	✓	✓	•	Injection	Yes

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Note: A - Active; I - Inactive

Yes/No relates to availability* of Formulation

PRODUCT NAME - COMMERCIAL*		THERAPY AREA	China DMF	US DMF	EU DMF	CEP	DOSAGE FORM	FORMULATION AVAILABILITY#
	Lomustine	Oncology	A	✓	•	✓	Capsules	No
	Losartan Potassium	Cardiology	•	✓	✓	✓	Tablets	Yes
	Lumateperone Tosylate	Central Nervous System	•	✓	•	•	Capsules	Yes
	Lurasidone Hydrochloride	Central Nervous System	A	✓	✓	•	Tablets	Yes
M	Memantine Hydrochloride	Central Nervous System	A	✓	•	•	Tablets/Capsules /Solution	Yes
	Metoprolol Succinate	Cardiology	A	✓	•	✓	Tablets	Yes
	Midostaurin (Amorphous and Form II)	Oncology	•	✓	•	•	Capsules	Yes
	Mirabegron (Alpha)	Urology	A	✓	✓	✓	Tablets	No
	Montelukast Sodium	Respiratory	A	✓	•	✓	Tablets	Yes
	Moxifloxacin Hydrochloride Anhydrous	Anti-Infective	•	✓	•	✓	Tablets/Injection	Yes
N	Naproxen Sodium	Pain Management	•	✓	•	✓	Tablets	Yes
	Naproxen	Pain Management	A	✓	•	✓	Tablets	Yes
	Naratriptan Hydrochloride	Pain Management	•	✓	✓	•	Tablets	No
	Nilotinib Hydrochloride	Oncology	A	✓	✓	✓	Capsules	Yes
	Nizatidine	Gastro-Intestinal	•	✓	•	✓	Capsules/Tablets	No
O	Olaparib (Form A)	Oncology	A	✓	•	•	Tablets	Yes
	Olanzapine (Form 1)	Central Nervous System	A	✓	•	✓	Tablets/Injection	Yes
	Omeprazole Magnesium (Amorphous & Crystalline)	Gastro-Intestinal	A	✓	✓	✓	Capsules	Yes
	Omeprazole Base (Crystalline)	Gastro-Intestinal	•	✓	✓	✓	Capsules	Yes
	Ondansetron Base	Oncology / Anti-Emetics	A	✓	✓	•	Tablets/Injection	Yes
	Ondansetron Hydrochloride	Oncology / Anti-Emetics	A	✓	•	✓	Tablets	Yes

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Note: A - Active; I - Inactive

Yes/No relates to availability* of Formulation

PRODUCT NAME - COMMERCIAL*		THERAPY AREA	China DMF	US DMF	EU DMF	CEP	DOSAGE FORM	FORMULATION AVAILABILITY#
P	Palbociclib	Oncology	•	✓	•	•	Capsules/Tablets	Yes
	Palonosetron Hydrochloride	Oncology / Anti-Emetics	•	✓	✓	•	Injection	Yes
	Pantoprazole Sodium	Gastro-Intestinal	A	✓	✓	✓	Capsules	Yes
	Pazopanib	Oncology	•	✓	✓	•	Tablets	Yes
	Pemetrexed Disodium Heptahydrate	Oncology	A	✓	•	✓	Injection	Yes
	Permethrin	Anti-Infective	•	✓	✓	✓	Cream/Lotion	NO
	Pioglitazone Hydrochloride	Anti-Diabetic	A	✓	✓	✓	Tablets	Yes
	Pomalidomide	Oncology	•	✓	•	•	Capsules	Yes
	Posaconazole	Anti-Infective	•	✓	•	•	Capsules/Tablets /Injection	Yes
	Pregabalin	Central Nervous System	A	✓	✓	✓	Tablets	Yes
Q	Quetiapine Fumarate	Central Nervous System	A	✓	✓	✓	Tablets	Yes
R	Rabeprazole Sodium (Form Y)	Gastro-Intestinal	A	✓	✓	✓	Capsules	Yes
	Raloxifene Hydrochloride	Musculoskeletal	A	✓	•	✓	Tablets	Yes
	Ramipril	Cardiology	A	✓	•	✓	Tablets	Yes
	Relugolix	Oncology	•	✓	•	•	Tablets	Yes
	Ripretinib	Oncology	•	✓	•	•	Tablets	No
	Risperidone	Central Nervous System	A	✓	✓	✓	Tablets/Injection	Yes
	Rivaroxaban	Cardiology	I	✓	✓	✓	Tablets	Yes
	Rivastigmine Hydrogen Tartrate	Central Nervous System	A	✓	✓	✓	Capsules/Solution	Yes
	Ropinirole	Central Nervous System	•	✓	•	✓	Tablets	Yes
	Roxadustat Monohydrate (Form A)	Nephrology	A	✓	•	•	Tablets	No
S	Sacubitril - Valsartan	Cardiology	A	✓	✓	•	Tablets	Yes

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Note: A - Active; I - Inactive

Yes/No relates to availability* of Formulation

PRODUCT NAME - COMMERCIAL*		THERAPY AREA	China DMF	US DMF	EU DMF	CEP	DOSAGE FORM	FORMULATION AVAILABILITY#
	Semaglutide	Diabetes and Obesity	•	✓	•	•	Injection/Tablets	Yes
	Siponimod Hemifumarate	Central Nervous System	•	✓	•	•	Tablets	Yes
	Sitagliptin Hydrochloride (Monohydrate)	Anti-Diabetic	•	✓	✓	•	Tablets	Yes
	Sitagliptin Phosphate (Anhydrous)	Anti-Diabetic	A	✓	•	•	Tablets	Yes
	Sitagliptin Phosphate (Monohydrate)	Anti-Diabetic	•	✓	•	✓	Tablets	Yes
	Sugammadex Sodium	Central Nervous System	A	✓	✓	•	Injection	Yes
	Sumatriptan Succinate	Pain Management	•	✓	•	✓	Tablets	Yes
T	Tafamidis Meglumine	Cardiology	•	✓	•	•	Capsules	Yes
	Terbinafine Hydrochloride	Anti-Infective	•	✓	•	✓	Tablets	Yes
	Testosterone	Urology	•	✓	•	•	Injection/Gel/Cream	No
	Ticagrelor	Cardiology	A	✓	✓	✓	Tablets	Yes
	Tizanidine Hydrochloride	Central Nervous System	•	✓	✓	✓	Tablets	Yes
	Tofacitinib Citrate (Crystalline Form A)	Others	•	✓	•	•	Tablets	No
	Travoprost	Others	•	✓	✓	•	Solution	No
	Treprostinil	Cardiology	•	✓	✓	•	Injection	Yes
	Tucatinib	Oncology	A	✓	•	•	Tablets	No
V	Valsartan	Cardiology	A	✓	✓	✓	Tablets	Yes
	Varenicline Tartrate	Others	•	✓	•	•	Tablets	Yes
	Voclosporin	Nephrology	•	✓	•	•	Capsules	Yes
	Vonoprazan Fumarate	Gastro-Intestinal	•	✓	•	•	Tablets	Yes
Z	Ziprasidone Hydrochloride Anhydrous	Central Nervous System	•	✓	✓	✓	Capsules	Yes
	Zoledronic Acid	Oncology	•	✓	✓	✓	Injection	Yes

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Note: A - Active; I - Inactive

Yes/No relates to availability* of Formulation

PRODUCT NAME - UNDER DEVELOPMENT*		THERAPY AREA	China DMF	US DMF	EU DMF	CEP	DOSAGE FORM	FORMULATION AVAILABILITY#
A	Acalabrutinib	Oncology	•	•	•	•	Capsules/Tablets	Yes
	Acoramidis	Cardiology	•	•	•	•	Tablets	Yes
	Adagrasib	Oncology	•	✓	•	•	Tablets	No
	Aficamten	Cardiology	•	•	•	•	Tablets	Yes
B	Brensocatib	Pulmonology	•	•	•	•	Tablets	Yes
C	Capivasertib	Oncology	•	•	•	•	Tablets	Yes
E	Elinzanetant	Women's Health	•	•	•	•	Tablets	Yes
F	Fruquintinib	Oncology	•	•	•	•	Capsules	No
I	Iptacopan	Haematology / Nephrology	•	•	•	•	Capsules	Yes
P	Perfluorohexyloctane	Ophthalmology	•	✓	•	•	Solution	Yes
R	Resmetirom	Non-alcoholic Steatohepatitis (NASH)	•	•	•	•	Tablets	Yes

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Note: A - Active; I - Inactive

Yes/No relates to availability* of Formulation

PRODUCT NAME - UNDER DEVELOPMENT*		THERAPY AREA	China DMF	US DMF	EU DMF	CEP	DOSAGE FORM	FORMULATION AVAILABILITY#
S	Seladelpar	Hepatology	•	•	•	•	Capsules	Yes
	Suzetrigine	Pain Management	•	•	•	•	Tablets	Yes
T	Tafamidis Free Acid	Cardiovascular	•	✓	•	•	Capsules	Yes
U	Upadacitinib	Immunology	•	•	•	•	Tablets	Yes
X	Xanomeline	Central Nervous System	•	•	•	•	Capsules	Yes (Combination with Trospium)

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Note: A - Active; I - Inactive

Yes/No relates to availability* of Formulation



FORMULATIONS

OUR VISION
TO REACH 1.5 BILLION
PEOPLE ACROSS THE
GLOBE

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patents related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
A	ABIRATERONE ACETATE	Tablets	250 and 500 mg	Oncology	Filed
	ACALABRUTINIB	Tablets	100 mg	Oncology	Under Development
	APALUTAMIDE	Tablets	60 mg	Oncology	Filed
	APIXABAN	Tablets	2.5 and 5 mg	Cardiovascular	Filed
	APREMILAST	Tablets	10, 20 and 30 mg	Psoriasis	Filed
	ARFORMOTEROL	Inhalation Solution	15 mcg/2 ml	Respiratory	Under Registration
	ATOGEPA NT	Tablets	10, 30 and 60 mg	Migraine	Under Registration
	ATORVASTATIN	Tablets	10, 20, 40 and 80 mg	Cardiovascular	Filed
	AZACITIDINE	Injection	100 and 150 mg	Oncology	Filed
B	BARICITINIB	Tablets	1, 2 and 4 mg	Rheumatoid arthritis	Under Development
	BEMPEDOIC ACID	Tablets	180 mg	Cardiovascular	Filed
	BEMPEDOIC ACID+EZETIMIBE	Tablets	180 mg	Cardiovascular	Filed
	BENDAMUSTINE	RTD Injection	180 mg	Oncology	Filed
	BENDAMUSTINE	Injection	25, 100 mg/vial	Oncology	Filed
	BORTEZOMIB	Lyo Injection	3.5 mg	Oncology	Filed
	BRIMONIDINE	Ophthalmic Solution	0.03%	Ophthalmology	Filed
C	CABAZITAXEL	Injection	40 mg/ml (1.5 ml)	Oncology	Filed
	CABOZANTINIB	Tablets	20, 40 and 60 mg	Oncology	Under Development
	CALCITONIN	Liquid Injection	200 IU/ml	Paget's disease	Filed
	CAPECITABINE	Tablets	150 and 500 mg	Oncology	Filed
	CARBIDOPA + LEVODOPA	ER Capsules	36.3mg+145mg, 23.8mg+95mg, 48.8mg+195mg and 61.3mg+245mg	Central Nervous System	Filed
	CARBOPROST	PFS Injection	250 mcg/ml	Women’s health	Filed
	CARFILZOMIB	Injection	10, 30 and 60 mg	Oncology	Filed

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
CARMUSTINE		Injection	100 mg	Oncology	Filed
CELECOXIB		Oral Solution	25 mg/1 ml	Pain Management	Filed
CINACALCET		Tablets	30, 60 and 90 mg	Endocrinology	Filed
CIPROFLOXACIN + DEXAMETHASONE		Ear Drops	0.3% + 0.1% 7.5 ml	Otolaryngology (ENT)	Filed
COLCHICINE		Tablets	0.6 mg	Central Nervous System	Filed
CYCLOPHOSPHAMIDE		RTD Injection	0.5, 1 and 2 gm	Oncology	Filed
D	DABIGATRAN ETEXILATE	Capsules	75, 110 and 150 mg	Cardiovascular	Filed
	DAPAGLIFLOZIN	Tablets	5 and 10 mg	Anti-Diabetic	Filed
	DAPAGLIFLOZIN+METFORMIN	XR Tablets	5 + 1000 mg and 10 + 1000 mg	Anti-Diabetic	Under Registration
	DAPAGLIFLOZIN+METFORMIN	IR Tablets	5 + 850 mg and 5 + 1000 mg	Anti-Diabetic	Under Registration
	DAPTOMYCIN	Injection	350 and 500 mg	Anti-Infective	Filed
	DASATINIB MONOHYDRATE	Tablets	20, 50, 70, 80, 100 and 140 mg	Oncology	Filed
	DECITABINE	Injection	50 mg/vial	Oncology	Filed
	DESMOPRESSIN	Injection	4 mcg/ml	Endocrinology/Urology	Filed
	DEXLANSOPRAZOLE	DR Capsules	30 and 60 mg	Gastroenterology	Under Development
	DIFLUPREDNATE	Eye Drops	0.05%	Ophthalmology	Filed
	DIMETHYL FUMARATE	Capsules	120 and 240 mg	Multiple sclerosis	Under Registration
	DOLUTEGRAVIR+LAMIVUDINE	Tablets	50 + 300 mg	HIV	Under Development
	DOLUTEGRAVIR+RILPIVIRINE	Tablets	50 + 25 mg	HIV	Under Development
E	EDARAVONE	Injection	60 mg/100 ml	Central Nervous System	Filed
	EDOABAN	Tablets	15, 30 and 60 mg	Cardiovascular	Filed
	ELIGLUSTAT	Capsules	84 mg	Type 1 Gaucher disease	Filed

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
	ELTROMBOPAG	Tablets	12.5, 25, 50 and 75 mg	Anemia	Filed
	EMPAGLIFLOZIN	Tablets	10 and 25 mg	Anti-Diabetic	Filed
	EMPAGLIFLOZIN + LINAGLIPTIN	Tablets	10 + 5 mg and 25 + 5 mg	Anti-Diabetic	Under Registration
	ENZALUTAMIDE	Tablets	40 and 80 mg	Oncology	Filed
	ENZALUTAMIDE	Soft gel Capsules	40 mg	Oncology	Filed
	EPHEDRINE	Injection	50 mg/ml	Anti-Allergic	Filed
	EPINEPHRINE	Injection	10 mg/10 ml and 30 mg/30 ml	Anti-Allergic	Filed
	ERIBULIN	Injection	1mg/2ml	Oncology	Filed
	ESOMEPRAZOLE	DR Capsules	20 and 40 mg	Gastroenterology	Filed
	ESOMEPRAZOLE+ NAPROXEN	Tablets	20 + 375 mg and 20 + 500 mg	Gastroenterology	Filed
	EVEROLIMUS	Tablets	2.5, 5, 7.5 and 10 mg	Oncology	Filed
F	FERRIC CARBOXY MALTOSE	Injection	50 mg/ml	Anemia	Filed
	FIDAXOMICIN	Tablets	200 mg	Anti-Infective	Under Development
	FINGOLIMOD	Capsules	0.5 mg	Multiple sclerosis	Filed
	FONDAPARINUX SODIUM	PFS Injection	"2.5 mg/0.5 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml and 10 mg/0.8 ml"	Cardiovascular	Filed
	FORMOTEROL FUMARATE	Inhalation Solution	20 mcg/2 ml	Respiratory	Filed
	FOSAPREPITANT	Injection	150 mg	Oncology (Supportive Care)	Filed
	FULVESTRANT RT	PFS Injection	250 mg/5 ml	Oncology	Filed
H	HYDROCORTISONE SODIUM SUCCINATE	Injection	100 mg	Anti-Inflammatory	Under Registration
I	IMATINIB	Capsules	100 and 400 mg	Oncology	Filed
	IMATINIB	Tablets	100 and 400 mg	Oncology	Filed
	ISOTRETINOIN	Capsules	10, 20, 30 and 40 mg	Acne	Filed

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
K	KETOROLAC	Injection	30 mg/ ml	Pain Management	Filed
	KETOROLAC	Tablets	10 mg	Pain Management	Filed
L	LACOSAMIDE	Injection	200 mg/20 ml	Central Nervous System	Filed
	LANSOPRAZOLE	OD Tablets	15 and 30 mg	Gastroenterology	Filed
	LATANOPROSTENE BUNOD	Ophthalmic Solution	0.024%	Ophthalmology	Filed
	LENALIDOMIDE	Capsules	2.5, 5, 10, 15, 20 and 25 mg	Oncology	Filed
	LENVATINIB	Capsules	4 and 10 mg	Oncology	Filed
	LETERMOVIR	Tablets	240 and 480 mg	Infectious Disease (CMV)	Under Development
	LINAGLIPTIN	Tablets	5 mg	Anti-Diabetic	Filed
	LINAGLIPTIN+METFORMIN	Tablets	2.5 mg/500 mg, 2.5 mg/ 850 mg and 2.5 mg/1 g	Anti-Diabetic	Filed
	LIRAGLUTIDE	Injection Pen	6 mg/ml (3 ml)	Obesity	Filed
	LIRAGLUTIDE	Injection Pen	6 mg/ml (3 ml)	Anti-Diabetic	Filed
	LOXOPROFEN	Powder for Oral Solution - Sachet	60 mg	Pain Management	Filed
	LOXOPROFEN	Tablets	60 mg	Pain Management	Filed
	LUMATEPERONE	Tablets	10.5, 21 and 42 mg	Central Nervous System	Filed
M	MIDOSTAURIN	Soft gel Capsules	25 mg	Oncology	Filed
N	NALOXONE	Injection	2 mg/2 ml	Central Nervous System	Filed
	NANO PACLITAXEL	Injection	100 mg	Oncology	Filed
	NAPROXEN	Tablets	275 and 550 mg	Pain Management	Filed
	NELARABINE	Injection	250 mg/50 ml	Oncology	Filed
	NEOSTIGMINE	Injection	0.5 mg/1 ml, 1 mg/ ml and 3 mg/3 ml	Myasthenia gravis	Filed
	NICOTINE	Mini Lozenges	2 and 4 mg	Smoking Cessation	Under Development
	NILOTINIB	Capsules	50, 150 and 200 mg	Oncology	Filed
	NINTEDANIB	Soft gel Capsules	100 and 150 mg	Oncology	Filed

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
O	OLAPARIB	Tablets	100 and 150 mg	Oncology	Under Development
P	PALBOCICLIB	Tablets	75, 100 and 125 mg	Oncology	Filed
	PALBOCICLIB	Capsules	75, 100 and 125 mg	Oncology	Filed
	PALONOSETRON	Injection	0.075 mg/5 ml and 0.25 mg/ 5 ml	Anti-Emetic	Filed
	PAZOPANIB	Tablets	200 and 400 mg	Oncology	Filed
	PEMETREXED	Injection	100 mg/vial, 500 mg/vial and 1 g/vial	Oncology	Filed
	PLERIXAFOR	Injection	24 mg/1.2 ml	Oncology (Supportive Care)	Filed
	POMALIDOMIDE	Capsules	1, 2, 3 and 4 mg	Oncology	Filed
	POSACONAZOLE	DR Tablets	100 mg	Anti-Infective	Filed
	PRALATREXATE	Injection	20 mg/ml and 40 mg/2 ml	Oncology	Filed
	PREDNISOLONE ACETATE	Ophthalmic Suspension	1%	Ophthalmology	Under Development
R	REGADENOSON	Injection	0.4 mg/5 ml	Cardiovascular	Filed
	REGORAFENIB	Tablets	40 mg	Oncology	Filed
	RELUGOLIX	Tablets	120 mg	Oncology	Filed
	RIFAXIMIN	Tablets	550 mg	Anti-Infective	Under Development
	RIVAROXABAN	Tablets	2.5, 10, 15 and 20 mg	Cardiovascular	Filed
S	SACUBITRIL+VALSARTAN	Tablets	24/26, 49/51 and 97/103 mg	Cardiovascular	Filed
	SAPROTERIN	Powder for Oral Solution	100 mg	Phenylketonuria	Under Registration
	SAPROTERIN	Tablets	100 mg	Phenylketonuria	Under Registration
	SELATOGREL	Injection	16 mg/0.5 ml	Cardiovascular	Early stage of Development
	SEMAGLUTIDE	Injection	2 mg/1.5 ml, 2 mg/3 ml, 4 mg/3 ml and 8 mg/3 ml	Anti-Diabetic	Filed

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
	SEMAGLUTIDE	Tablets	3, 7 and 14 mg	Anti-Diabetic	Filed
	SEMAGLUTIDE	Tablets	1.5, 4 and 9 mg	Anti-Diabetic Obesity	Under Development
	SEMAGLUTIDE	Injection Pen	1 mg/1.5 ml, 2 mg/1.5 ml, 4 mg/3 ml, 6.8 mg/3 ml and 9.6 mg/3 ml	Obesity	Under Development
	SEVELAMER	Powder for Oral Suspension	800 mg and 2.4 gm	Urology	Filed
	SEVELAMER	Tablets	800 mg	Urology	Filed
	SIPONIMOD	Tablets	0.25, 1 and 2 mg	Multiple sclerosis	Filed
	SIROLIMUS	Tablets	1, 2 mg	Immunosuppressant	Filed
	SITAGLIPTIN	Tablets	25, 50 and 100 mg	Anti-Diabetic	Filed
	SITAGLIPTIN +METFORMIN	Tablets	50 + 500 mg and 50 + 1000 mg	Anti-Diabetic	Filed
	SODIUM NITROPRUSSIDE	Injection	50 mg/2 ml	Cardiovascular	Filed
	SORAFENIB	Tablets	200 mg	Oncology	Filed
	SUGAMMADEX	Injection	100 mg/ml (2 ml and 5 ml)	Central Nervous System	Filed
	SUNITINIB	Capsules	12.5, 25, 37.5 and 50 mg	Oncology	Filed
T	TACROLIMUS	Capsules	0.5, 1 and 5 mg	Immunosuppressant	Filed
	TAFAMIDIS MEGLUMINE	Soft gel Capsules	21 mg	Cardiovascular	Under Registration
	TAPINAROF	Cream	1%	Plaque psoriasis	Under Development
	TELMISARTAN + AMLODIPINE	Tablets	40 + 5 mg, 40 + 10 mg, 80 + 5 mg and 80 + 10 mg	Cardiovascular	Filed
	TERIPARATIDE	Injection	0.25 mg/ml (2.4 ml)	Anti-Osteoporosis	Filed
	TICAGRELOR	Tablets	60 and 90 mg	Cardiovascular	Filed
	TIMOLOL MALEATE	Ophthalmic Gel forming Solution	0.25% and 0.50%	Ophthalmology	Filed
	TOPIRAMATE	XR Capsules	25, 50, 100 and 200 mg	Central Nervous System	Filed
	TREPROSTINIL	Injection	1 mg/ml, 2.5 mg/ml, 5 mg/ml and 10 mg/ml (20 ml)	Cardiovascular	Filed
	TRIAMCINOLONE ACETONIDE	Injection	50 mg/5 ml, 40 mg/1ml, 200 mg/5 ml and 400 mg/10 ml	Anti-Inflammatory	Filed
	TRILACICLIB DIHYDROCHLORIDE	Injection	300 mg	Oncology	Filed

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
U	UPADACITINIB	ER Tablets	15, 30 and 45 mg	Rheumatoid arthritis	Under Development
	UPADACITINIB	Oral Solution	1 mg/ml	Rheumatoid arthritis	Under Development
V	VALGANCICLOVIR	Tablets	450 mg	Anti-Viral	Filed
	VARENICLINE	Tablets	0.5 and 1 mg	Smoking cessation	Filed
	VASOPRESSIN	Injection	20 IU/ml	Endocrinology	Filed
	VIGABATRIN	Powder for Oral Solution - Sachet	500 mg	Central Nervous System	Filed
	VIGABATRIN	Tablets	500 mg	Central Nervous System	Filed
	VITAMIN K1	Injection	10 mg/ml	Hematology	Filed
	VOCLOSPORIN	Soft Gel Capsules	7.9 mg	Nephrology	Under Registration
	VONOPRAZAN	Tablets	10 and 20 mg	Gastroenterology	Under Registration
	VORICONAZOLE	Tablets	50 and 200 mg	Anti-Infective	Filed
Z	ZAFIRLUKAST	Tablets	10 and 20 mg	Respiratory	Filed

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

Get the
product list -
just scan the
QR code!



Scan to
follow ourAPI
LinkedIn
Handle!





Dr.Reddy's 

api.drreddys.com | api@drreddys.com

Published date: 2nd July, 2026

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patents related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.